Miguel-teodoro Hernandez

Santa Cruz De Tenerife, CN, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma.

Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 01, 2024

Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.

Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.

Journal: Annals of hematology

Published: July 24, 2024

Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.

Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.

Journal: Haematologica

Published: August 25, 2023

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma.

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma.

Journal: Blood

Published: August 03, 2023

Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.

Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 17, 2023

NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial.

NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial.

Journal: Cancers

Published: September 16, 2022

Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma.

Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 06, 2022

Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study.

Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 29, 2022

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.

Journal: Blood cancer journal

Published: January 11, 2022

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.

Journal: Blood advances

Published: December 03, 2021

A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma.

A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 22, 2021

Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?

Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?

Journal: Blood

Published: May 04, 2021

Showing 1-12 of 21

Last Updated: 09/26/2026